These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 1379914

  • 1. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
    Faulds D, Brogden RN.
    Drugs; 1992 Jul; 44(1):94-116. PubMed ID: 1379914
    [Abstract] [Full Text] [Related]

  • 2. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
    Perry CM, Balfour JA.
    Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
    [Abstract] [Full Text] [Related]

  • 3. AIDS: Part II.
    Kessler HA, Bick JA, Pottage JC, Benson CA.
    Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
    [Abstract] [Full Text] [Related]

  • 4. Didanosine: an updated review of its use in HIV infection.
    Perry CM, Noble S.
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [Abstract] [Full Text] [Related]

  • 5. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [Abstract] [Full Text] [Related]

  • 6. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink HJ, Schrappe M, Stoehr A, Haase W, Schomaker U, von Eisenhart Rothe B.
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
    Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L.
    Ann Intern Med; 1993 Oct 15; 119(8):786-93. PubMed ID: 8379600
    [Abstract] [Full Text] [Related]

  • 8. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC.
    N Engl J Med; 1996 Oct 10; 335(15):1081-90. PubMed ID: 8813038
    [Abstract] [Full Text] [Related]

  • 9. Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.
    Moreno S, Hernández B, Dronda F.
    Drugs; 2007 Oct 10; 67(10):1441-62. PubMed ID: 17600392
    [Abstract] [Full Text] [Related]

  • 10. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D.
    N Engl J Med; 1996 Oct 10; 335(15):1099-106. PubMed ID: 8813040
    [Abstract] [Full Text] [Related]

  • 11. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA.
    Ann Intern Med; 1995 Oct 15; 123(8):561-71. PubMed ID: 7677296
    [Abstract] [Full Text] [Related]

  • 12. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS.
    Ann Intern Med; 1996 Jun 15; 124(12):1019-30. PubMed ID: 8633815
    [Abstract] [Full Text] [Related]

  • 13. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G.
    N Engl J Med; 1992 Aug 27; 327(9):581-7. PubMed ID: 1353607
    [Abstract] [Full Text] [Related]

  • 14. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
    d'Arminio Monforte A, Musicco M, Galli M, Paga C, La Regina A, Lazzarin A, Angarano G, Milazzo F, Gritti F, Arlotti M, Mazzotta F, Visco G, Aiuti F, Moroni M.
    Eur J Clin Microbiol Infect Dis; 1997 Feb 27; 16(2):135-42. PubMed ID: 9105840
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE.
    Am J Med; 1991 Nov 27; 91(5):471-8. PubMed ID: 1659189
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.